Heart Failure With Improved Ejection Fraction and Deep Learning
NCT ID: NCT06070506
Last Updated: 2023-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
422 participants
OBSERVATIONAL
2022-03-01
2023-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Heart Failure With Preserved Ejection Fraction
NCT03197350
Application of Multimodal Large Language Model in HFpEF
NCT06486649
Point of Care Artificial Intelligence Tool for Heart Failure Diagnosis
NCT04601415
Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation
NCT06555757
Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction
NCT05496439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HFrEF group
Heart failure patients with LVEF persistently ≤40%.
No interventions assigned to this group
HFimpEF group
Heart failure patients with previous LVEF ≤40% and a follow-up LVEF of more than 40%.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The diagnostic criteria of HF follows the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, having symptoms of dyspnea, fatigue or decreased activity tolerance, having signs of fluid retention (such as pulmonary congestion and peripheral edema), having echocardiogram abnormalities in cardiac structure and/or function, showing elevated natriuretic peptide levels (BNP\>35 ng/L or/and N-terminal pro-BNP \>125 ng/L).
3. Have reviewing echocardiography after discharge.
Exclusion Criteria
2. Patients with heart transplantation during follow-up.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yihui Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yihui Kong
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yihui Kong
Harbin, Heilongjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020020668
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.